Navigation Links
Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
Date:6/18/2012

WASHINGTON, June 18, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that Michael Cola has joined Vanda's Board of Directors. Mr. Cola will also serve as a member of the Audit Committee of the Board replacing Howard Pien, who will continue to serve as the Chairman of the Board and as a member of each of the Compensation Committee and the Nominating/Corporate Governance Committee of the Board.  In connection with Mr. Cola's election, the Board has increased the number of directors to seven.

"I would like to personally welcome Mike to our Board," said Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer of Vanda. "We are very fortunate to have someone with his breadth of pharmaceutical industry and leadership experience on our Board as we continue to develop and commercialize our clinical assets."

Mr. Cola served as President of Shire plc's Specialty Pharmaceuticals business from 2007 until April 2012. Mr. Cola joined Shire in July 2005 as Executive Vice President for Global Therapeutic Business Units and Portfolio Management prior to being named President of the Specialty Pharmaceuticals business. Prior to joining Shire, Mr. Cola spent more than five years at Safeguard Scientifics, where he served as President of the Life Sciences Group. As part of his role with Safeguard Scientifics, Cola served as Chairman and CEO of Clarient, a cancer diagnostics company, and Chairman of Laureate Pharma, a full service contract manufacturing organization serving research based biologics companies.  Prior to joining Safeguard Scientifics, Mr. Cola held progressively senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and later with AstraZeneca.  Mr. Cola currently serves on the Board of Directors of NuPathe Pharmaceuticals, is a member of the Board of Trustees of Ursinus College, and a member of the Board of Directors of Pennsylvania Bio, the statewide association representing the biosciences community.  Mr. Cola received his Bachelor of Arts degree in biology and physics from Ursinus College and his Master of Science degree in biomedical science from Drexel University.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(202) 734-3414
cristina.murphy@vandapharma.com

 

 


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
2. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
3. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
4. American Society of Hematology joins European Hematology Association, Patient Groups in Issuing International Call to Action to Alleviate Drug Shortages
5. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
6. Anthony Creed Joins DDSTUDIO As GM, Experience Design
7. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
8. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
9. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
10. David F. Harty Joins Systech International as Vice President
11. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)... YORK , Sept. 8, 2017 Dealmed ... largest independent supplier of medical equipment, supplies, drugs, vaccines, ... it has entered into an agreement to acquire Vantage ... equipment based in Holtsville, New York ... specializes in supplying new and emerging medical practices, will ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
Breaking Medicine News(10 mins):